Physicians and patients should continue treatment with their usual anti-hypertensive or diabetes management therapy, says the European Society of Cardiology (ESC). There is no evidence that ACEi or ARBs, drugs which upregulate Angiotensin Converting Enzyme (ACE), increase the risk of contracting COVID-19, the society said in a statement published March 13.
Awareness of the prevalence of hypertension has increased substantially over the past 40 years in high-income countries, as has treatment and control of the condition. But, the level of control falls short of rates seen in dedicated hypertension programs, and it’s stagnating, according to research published last month in The Lancet.
There are several reasonable options for intensifying this patient's blood pressure treatment. Which one is optimal, though, given his labs and concomitant meds?
In patients taking SGLT2 inhibitors who had treated hypertension, a new study found the drop in blood pressure seen with a diuretic similar to declines seen with other classes of antihypertensive medications.
The SGLT2 inhibitor in clinical trials was associated with decreases in systolic blood pressure. The current study looked specifically at the drug's effect on blood pressure--with encouraging results.
Contrave, a combination of naltrexone and buproprion, has been approved for long-term weight loss management in overweight and obese adults.
Lowering blood pressure is vital to care and should remain a priority in preventing and managing cardiovascular and microvascular complications.
Ambulatory blood pressure monitoring is a useful prognosis tool to differentiate between true and white coat resistant hypertension, according to a study published online March 28 in Hypertension.